Moreover, we have demonstrated that negative feedback can be overcome by inhibiting BRAF in both its monomeric and dimeric form in combination with MEK inhibition leading to more efficacious and tolerable treatment in preclinical BRAF (V600E) cancer models. This evidence concerns the gene BRAF and cancer.